FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

CADILAHC Share Price Discussion

Cadila Healthcare Ltd.
Sector: Pharmaceuticals and health care
... Read more
CADILAHC Long Term Analysts Rating
4.2/5 (19 Ratings)
CADILAHC Share Price *
268.95 -1.25 (-0.46%)
* (quote may be delayed)

Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?


You can also check CADILAHC share price target recommended by brokerages.

CADILAHC Discussion Forum

@Instinct • Reputation: 271
CADILAHC JAN20 FUT

Type
Sell
Instrument
CADILAHC JAN20 FUT
Entry Price
₹269.55
Price@Trade
₹269.55
Target Price
₹264
Stop Price
₹274
Valid Till
Jan 30, 2020 3:20 PM
Margin
₹104,801.81 approx for 2200 Qty
Status
Active
Like
reply
Reply
@mayurpatel • Reputation: 3,568
TREAD WITH TREND in CADILAHC
CADILA START AGAIN................................

272-----------------------
Like
reply
Reply
@mayurpatel • Reputation: 3,568
TREAD WITH TREND in CADILAHC
CADILA START AGAIN................................

271------------------------
Like
reply
Reply
@mayurpatel • Reputation: 3,568

CADILA START AGAIN.........................................
Like
reply
Reply
HALAL INVESTMENT in CADILAHC
CADILA...234 BUY RANGE...CMP TO 225 CBSL...220 ...

CADILA 271+
Like
reply
Reply

CADILA READY FOR BLASTTTTTTTTTTTTTTTTTTTTT
Like
reply
Reply
@commodityBiz • Reputation: 4,205

CADILAHC - chart - 507273
👆👆👆👆👆👆👆👆Suggestion :- SELL IF PRICE COMES AGAIN AT 256.50 WITH SL OF 258 FOR TARGET OF 254
EXPECTATION OF TARGET- 1 DAYS
SIGNAL TYPE - STRONG TIME FRAME- 1 HOURS
1
reply
Reply
@commodityBiz • Reputation: 4,205

CADILAHC - chart - 505595
👆👆👆👆👆👆👆👆Suggestion :- SELL IF PRICE COMES AGAIN BETWEEN 256 WITH SL OF 260 FOR TARGET OF 251
EXPECTATION OF TARGET- 1 DAYS
SIGNAL TYPE - STRONG TIME FRAME- 1 HOURS
Like
reply
Reply

Cadila Healthcare has clarified it had no plans to sell two of its divisions.
Like
reply
Reply (1)
Latest replies

Recent acquisition of Heinz India could be an overhang on Cadila Health: Citi. Target price Rs 240/Share.
@databot • Reputation: 1,301

Motilal Oswal target on CADILAHC
Date: 13-Nov-19 Broker: Motilal Oswal Price @ Call: 227.11 Target: 265 Recommendation: BUY
Like
reply
Reply
@databot • Reputation: 1,301

Motilal Oswal target on CADILAHC
Date: 13-Nov-19 Broker: Motilal Oswal Price @ Call: 227.11 Target: 265 Recommendation: BUY
Like
reply
Reply
@commodityBiz • Reputation: 4,205

CADILAHC - chart - 500620
👆👆👆👆👆👆👆👆Suggestion :- SELL IF PRICE COMES AGAIN AT 259 WITH SL OF 261 FOR TARGET OF 254
EXPECTATION OF TARGET- 1 DAYS
SIGNAL TYPE - STRONG TIME FRAME- 1 HOURS
Like
reply
Reply

Cadila Health care
Fundamental Strong company among Pharma Sector
Cmp @ 257.90 spot
Accumulate at cmp & on every dip
For short term tgt 260-266-271++
SL @ your own risk or Ping me for Levels
Reminder @
If break and sustain/close above 271.10 than showing strength for tgt 274-27...
Read more...
1
reply
Reply
@sifm • Reputation: 852

Short cadilahc @ 260.30 sl 262.50 tgt 257
Like
reply
Reply
@TTA • Reputation: 6,115

No Form 483 observations have been issued to Cadila Healthcare's topical manufacturing facility in Hyderabad at the end of USFDA inspection conducted from December 1620, 2019 POSITIVE FOR CADILLA
Like
reply
Reply
@rk30033 • Reputation: 16

CADILAHC - chart - 486909
I WILL BUY CADILA ABOVE 256 SL 247 TARGET- 285/290
Like
reply
Reply (2)
Latest replies
RAM KUMAR @rk30033
Dec 21 12:29 AM

CADILA TODAYS HIGH 268.20 Almost 4% From given levels. More to come
RAM KUMAR @rk30033
Dec 23 6:45 PM

CADILA AFTER HITTING HIGH 271 COMMING TO OUR BUY RANGE
@hidden • Reputation: 1,723

CADILAHC - 482658
CADILA HEALTH READY FOR 300++++
Like
reply
Reply
@invictotrader • Reputation: 2,013

Cadila Healthcare gains 4% on launch of anti-diabetic tablet in India Vinglyn and Vinglyn M will be marketed by Zydus Healthcare.
Like
reply
Reply
@TTA • Reputation: 6,115

Equirus on Cadila
Downgrade to SHORT, TP Rs 224
Expect earnings pressure even beyond FY22E amid
Limited high-value launches in pipeline
High concentration risk in existing biz
Longer gestation for monetization of vaccines
Assign lower P/E on higher concentration led by Asacol HD
Like
reply
Reply

💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY CADILA AT THE VERY BEGINING
STRICT STOP LOSS - 258
TARGET - 265/268
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please consult with your financial adviser before...
Read more...
Like
reply
Reply

 Cadila Healthcare launched the oral anti-diabetic tablets Vinglyn and Vinglyn M at an affordable price. The drug will help a large number of patients in India suffering from Type 2 diabetes.
Like
reply
Reply
@ENRITCHansraj • Reputation: 8,200

Cadila Healthcare : CO says inspection by US FDA of the company’s API manufacturing facility located at Dabhasa Gujarat, which stated that classification of the facility is no action indicated.
Like
reply
Reply
@invictotrader • Reputation: 2,013

Cadila Healthcare files NDA of Saroglitazar Mg with DCGI targeting liver diseases If the latest NDA is approved, Saroglitazar Mg could become the first medicine indicated for the treatment of Non-alcoholic Steatohepatitis (NASH).
Like
reply
Reply
@rajivkumarjha • Reputation: 17,909
robotrade in CADILAHC
Cadila healthcare fut 261 Buy Tgt 272/76 Sl 255...

264.5👈👈👈👈👈
Like
reply
Reply
@rajivkumarjha • Reputation: 17,909

Cadila healthcare fut 261
Buy
Tgt 272/76
Sl 255
Positional 7 day👈
Like
reply
Reply

BRIEF-Cadila Healthcare Unit Gets Tentative U.S. FDA Nod For Obesity Drug - Reuters
03-Dec-2019 11:19:58 AM
Dec 3 (Reuters) - Cadila Healthcare Ltd CADI.NS:
ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR LORCASERIN HYDROCHLORIDE TABLETS
Like
reply
Reply
@nishantshah91 • Reputation: 3,355

Cadila Healthcare board approves merger of four subsidiaries to consolidate pharma business
"The amalgamation is being done for consolidation of pharmaceutical business and merger simplification of corporate structure to avoid duplication of effort and to reduce the overheads and...
Read more...
Like
reply
Reply

BOOK PROFIT IN CADILAHC@262
Like
reply
Reply

Short Term Cash Buy CADILAHC @254.95-256.25 SL 251.5 TGT 265
Like
reply
Reply
@tradingfab • Reputation: 720

27-11-19
CADILAHC SELL FUT NOV (Intraday)
only below @ 254.50
Like
reply
Reply (1)
Latest replies
Sameer  @tradingfab
Nov 27 6:37 PM

LOW 252.65 **********************
INTRADAY TADKA in CADILAHC
FUTURE LOVER #CADILAHC FUT BUY ABOVE 257 TGT OPEN

#CADILAHC FUT FIREDDD MADE HIGH 260.40
(4800 PROFIT)
Like
reply
Reply

FUTURE LOVER
#CADILAHC FUT BUY ABOVE 257 TGT OPEN
Like
reply
Reply

CADILA HEALTHCARE LTD - ZYDUS RECEIVES FINAL APPROVALS FROM USFDA FOR ISOSORBIDE DINITRATE TABLETS AND DESONIDE CREAM
Like
reply
Reply
@RJhariya • Reputation: 0

BUY CADILAH ABOVE 252 SL 247 TGT 260
Like
reply
Reply
HALAL INVESTMENT in CADILAHC
CADILA...234 BUY RANGE...CMP TO 225 CBSL...220 ...

CADILA 234 TO 251+
Like
reply
Reply
@TTA • Reputation: 6,115

Cadila Healthcare-2QFY20 Result Update-14 November 2019.pdf
510 KB
Cadila Healthcare
US sales help performance, but other expense increases sharply
Like
reply
Reply
@ENRITCHansraj • Reputation: 8,200
Hansraj pandey in CADILAHC
BUY CADILA HC 239-240 STOP LOSS 235 TARGET 24...

CADILAHC FINAL TGT🎯🎯🎯 DONE BOOK HUGE PROFIT AGAIN 🚀🚀
Like
reply
Reply
@ENRITCHansraj • Reputation: 8,200
Hansraj pandey in CADILAHC
BUY CADILA HC 239-240 STOP LOSS 235 TARGET 24...

🎯🎯🎯Made ahigh 242.60cmp 242.40 till tym profit 3200/-💪
Like
reply
Reply
@ENRITCHansraj • Reputation: 8,200

BUY CADILA HC 239-240 STOP LOSS 235 TARGET 243/247
Like
reply
Reply (2)
Latest replies
Vinod raj @vinodraj
Nov 18 3:52 PM

Stop-loss hit

Vinod. Seen my trade. Till time not executed

CADILA...234
BUY RANGE...CMP TO 225
CBSL...220
EXPECT TARGET...260/275+
Like
reply
Reply
@databot • Reputation: 1,301

Karvy Stock Broking target on CADILAHC
Date: 15-Nov-19 Broker: Karvy Stock Broking Price @ Call: 234.2 Target: 274 Recommendation: BUY
Like
reply
Reply
@rah-Sy96_oTMS • Reputation: 32

buy cadilahc 229/- sl 227 tr 232/5----233/5
Like
reply
Reply
@TTA • Reputation: 6,115

MS on Cadila
Earnings concentration is waning
Profit base is getting normalized, though gAsacol HD remains
Steady growth, IP optionality & reasonable valuation keep us OW, TP Rs 304
Like
reply
Reply
@TTA • Reputation: 6,115

CS On Cadila
Neutral, TP Rs 251
Good Performance In US & India; Profit Concentration Still High
Quarter Impacted By Wellness Seasonality & Rise In India Biz Expenses
US Base Biz Growth Guidance Maintained At High Single-digit
Moraiya Clearance Unlikely Before H2FY21
Like
reply
Reply
@umanath • Reputation: 563

CADILAHC - 437547

Like
reply
Reply

Cadila Healthcare Buys 15% Stake In Zydus Technologies
ACQUIRED 15% EQUITY SHARE CAPITAL OF ZYDUS TECHNOLOGIES
ALSO ACQUIRED 15% COMMON STOCK OF ZYDUS NOVELTECH INC., USA
5
reply
Reply

BUY CADILA ABOVE ⬆️ 237 TGS 239 » 241 » 243 UPTO 245 SL 233
Like
reply
Reply
@nishantshah91 • Reputation: 3,355

Cadila Healthcare Falls 9% After U.S. FDA Issues Warnings Letter
The Company has taken multiple steps after the inspection to address the observations received from US FDA during the inspection. The Company will continue to take all necessary steps to ensure that the US FDA is...
Read more...
1
reply
Reply

BRIEF-Cadila Healthcare Gets Warning Letter Issued By US FDA Relating To Moraiya Formulation Facility - Reuters
Like
reply
Reply

BRIEF-Cadila Healthcare Gets Warning Letter Issued By US FDA Relating To Moraiya Formulation Facility - Reuters
04-Nov-2019 02:36:01 PM
Nov 4 (Reuters) - Cadila Healthcare Ltd CADI.NS:
. - WARNING LETTER - US FDA
SAYS COMPANY HAS RECEIVED A WARNING LETTER ISSUED BY US FDA RELATIN...
Read more...
Like
reply
Reply
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC Share Price - Technicals

    keyboard_arrow_down
    CADILAHC - 52 Week High₹358.4
    CADILAHC - 52 Week Low₹206.5
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    15-Nov-19Karvy Stock BrokingBuy274
    13-Nov-19Motilal OswalBuy265
    13-Aug-19Nirmal BangBuy315
    13-Aug-19Karvy Stock BrokingHold261
    10-Aug-19HDFC SecuritiesBuy265
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 17271.9272.8266.7269.15
    Jan 16262.8271.7262.1270.2
    Jan 15257.05263.85255.8262.75
    Jan 14256.55258.5255257.05
    Jan 13258259.5255.8256.55
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹259.12
    30 Day Moving Average₹259.56
    50 Day Moving Average₹254.77
    100 Day Moving Average₹246.13
    200 Day Moving Average₹255.79
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 17 4:28 PM
    Initiate long positions in auto, banks, metal stocks; IndusInd Bank ripe for bounce back
    Moneycontrol
    NewsBot
    Oct 14 9:28 PM
    Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 14 1:53 PM
    Stocks in the news: Infosys, Avenue Supermart, BoB, NMDC, Cadila Health, HUL
    Moneycontrol
    NewsBot
    Oct 10 1:38 AM
    Indian pharma market sees growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 9 11:08 PM
    Indian pharma market registers growth of 11.5% in Q2FY20
    Moneycontrol
    NewsBot
    Oct 9 7:33 PM
    Cadila Healthcare gains 4% on USFDA approval for cholesterol-lowering drug
    Moneycontrol
    NewsBot
    Oct 1 1:43 PM
    Stocks in the news: PNB, Bank of Baroda, Cadila, NBCC, BPCL, SCI, CG Power, PNB Housing
    Moneycontrol
    NewsBot
    Oct 1 1:28 PM
    Stocks in the news: PNB, Bank of Baroda, Cadila, NBCC, BPCL, SCI
    Moneycontrol
    NewsBot
    Oct 1 12:53 PM
    A morning walk down Dalal Street | Technical indicators show Nifty may move up towards 11,600-11,700
    Moneycontrol
    NewsBot
    Oct 1 3:18 AM
    Cadila inks pact to sell rights of cholesterol lowering drug in US, Canada to Medicure
    Moneycontrol
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Strides Pharma Science Ltd. Sector: P...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.